Main Products
▪ DC105, a first-in-class drug for abdominal pain in irritable bowel syndrome (IBS) ▪ Demonstrate potent and long-lasting analgesic effect for IBS visceral pain after oral administration ▪ Exhibit high safety and therapeutic index ▪ Seeking fundraising opportunities to conduct IND-enabling preclinical GLP studies
Business Interests
Out-Licensing, Co-Development, Fundraising、M&A
Contact Info
Jack Hsin
CEO
+886-919381624
xin@lyntonix.com